Universität zu Köln

Harbeck, Nadia, Salem, Marwa, Nitz, Ulrike, Gluz, Oleg and Liedtke, Cornelia (2010). Personalized treatment of early-stage breast cancer: Present concepts and future directions. Cancer Treat. Rev., 36 (8). S. 584 - 595. OXFORD: ELSEVIER SCI LTD. ISSN 1532-1967

Full text not available from this repository.

Abstract

Breast cancer is the most common malignancy in women. Effective loco-regional as well as systemic treatment options have rendered breast cancer a curable disease for the vast majority of early-stage patients. Considering tumor biology and clinical outcomes, breast cancer is a very heterogeneous disease. With the recent understanding of distinct molecular sub-types, the era of one size fits all therapy concepts has passed and a new era of personalized therapy concepts has started. This review will focus on recent advances in personalized treatment of early-stage breast cancer, with a particular interest in tumor biology-guided treatment decisions. It will also highlight how carefully molecular tests need to be methodologically and clinically validated before they can be applied for clinical decision making. (C) 2010 Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Harbeck, Nadia UNSPECIFIED UNSPECIFIED UNSPECIFIED Salem, Marwa UNSPECIFIED UNSPECIFIED UNSPECIFIED Nitz, Ulrike UNSPECIFIED UNSPECIFIED UNSPECIFIED Gluz, Oleg UNSPECIFIED UNSPECIFIED UNSPECIFIED Liedtke, Cornelia UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-491226
DOI:	10.1016/j.ctrv.2010.04.007
Journal or Publication Title:	Cancer Treat. Rev.
Volume:	36
Number:	8
Page Range:	S. 584 - 595
Date:	2010
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1532-1967
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GENE-EXPRESSION PROFILES; PLASMINOGEN-ACTIVATOR UPA; TOPOISOMERASE-II-ALPHA; ADJUVANT CHEMOTHERAPY; HIGH-RISK; PROGNOSTIC SIGNATURE; ENDOCRINE THERAPY; CLINICAL UTILITY; TAMOXIFEN PHARMACOGENOMICS; ENHANCED BENEFIT Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/49122